Poolbeg Pharma has received formal notification of the decision to grant its POLB 001 cancer immunotherapyinduced Cytokine Release Syndrome (CRS) patent application from the European Patent Office, representing the most commercially significant milestone to date within Poolbeg’s cancer immunotherapy-induced CRS patent family. The grant provides protection across key European markets, one of the largest and most valuable pharmaceutical regions globally, and follows recent patent awards in Austral ....
